New application of a stabilized active cyclophosphamide derivative (Mafosfamide, ASTA Z 7654) — immunogenic properties of lymphatic leukemia L 1210 cells treatedin vitrowith the drug
✍ Scribed by Tomasz Skórski; Maciej Kawalec
- Book ID
- 104662280
- Publisher
- Springer US
- Year
- 1987
- Tongue
- English
- Weight
- 208 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
✦ Synopsis
Lymphatic leukemia L 1210 cells were treated in vitro with various concentrations of Mafosfamide -a stabilized active derivative of cyclophosphamide (4-hydroxycyclophosphamide). L 1210 cells treated with Mafosfamide (L 1210-MAF cells) were used for vaccination of semisyngeneic CD2F 1 mice against L 1210 leukemia. These cells do not grow in vivo but are viable in the test with trypan blue. L 1210-MAF cells, obtained by treatment of L 1210 cells two times with 50/xg/ml or 100/xg/ml of Mafosfamide, and injected into the mice induced resistance against L 1210 leukemia in these animals. L 1210 cells treated two times with higher concentration of Mafosfamide (200/xg/ml or 400/zg/ml) did not give this effect.